Source comparison
Dosing, Storage, and Practical Considerations for Follistatin-344 vs MK-677
Follistatin-344 is supplied as lyophilized powder requiring reconstitution with bacteriostatic water before administration. Standard research dosing ranges from 100–300mcg per injection, administered subcutaneously or intramuscularly depending on protocol desi
This comparison does not assign a generated winner or score.
- Follistatin-344 is supplied as lyophilized powder requiring reconstitution with bacteriostatic water before administration. Standard research dosing ranges from 100–300mcg per injection, administered subcutaneously or intramuscularly depending on protocol design. Because follistatin-344 has a short half-life of 3–4 hours, research protocols typically implement twice-daily dosing to maintain plasma concentrations above the threshold required for myostatin binding. Unreconstituted follistatin-344 must be stored at −20°C; once reconstituted, refrigerate at 2–8°C and use within 14–21 days. Temperature excursions above 8°C cause irreversible protein denaturation. The glycoprotein structure unfolds and loses binding affinity for myostatin. We manufacture follistatin-344 through small-batch synthesis with exact amino acid sequencing to guarantee structural integrity, but storage protocol adherence is the researcher's responsibility.
- MK-677 is available in both powder and capsule form. As a small-molecule ghrelin mimetic rather than a peptide, MK-677 demonstrates superior stability. No refrigeration required when stored as powder, and capsule formulations maintain potency at room temperature for 12–24 months. Research dosing ranges from 10–25mg once daily, typically administered in the evening to align with endogenous growth hormone pulsatility during sleep. The 24-hour half-life eliminates the need for split dosing. MK-677 doesn't require reconstitution, reducing preparation time and contamination risk compared to injectable peptides.
- The practical differences in follistatin-344 vs MK-677 handling affect research feasibility. Follistatin-344 protocols require: injection supplies, cold chain storage, reconstitution expertise, and twice-daily administration schedules. MK-677 protocols require: capsule or powder measurement and single daily oral administration. For laboratories without consistent cold storage or researchers prioritizing protocol simplicity, MK-677 presents fewer logistical barriers. Follistatin-344's complexity is justified when myostatin inhibition is the explicit research target. Otherwise, the added handling requirements introduce failure points without mechanistic benefit. Real Peptides provides MK 677 in both forms, but researchers should assess their cold chain capabilities before selecting follistatin-344 over an orally bioavailable alternative.